ClinicalTrials.gg
CompletedNCT01772134Updated Jan 29, 2018Results posted

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

A Phase 3 interventional study of Umeclidinium bromide 62.5mcg and Umeclidinium bromide 125mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 73 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-01-29.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
617
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline — 7 open to participants now, 8 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · GlaxoSmithKline.

Enrollment
48th of 236
617 · median 101
Started
2013
with 19 others
Phase 3
65 of 276
5 open now
Registered
164th of 276
by date

Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 48th largest by enrollment of the 236 interventional ones that give a count, is one of 20 that started in 2013, is one of 65 in phase 3, and was the 164th registered.

Pulmonary Disease, Chronic Obstructive

5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticanse propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to fluticanse propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticanse propionate/salmeterol (250/50mcg) twice-daily on lung function, COPD-related health status assessments and safety in COPD subjects.

Read the detailed description

This is a mutlicenter, randomized, double-blind, parallell-group study. Subejcts who meet the eligibility criteria at screening and meet the randomization criteria at the end of a 4 week run-in period will enter a 12 week treatment period. There will be a 7 day follow-up period after the treatment period.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -Type of subject: Outpatient.
  • : A signed and dated written informed consent prior to study participation.
  • Age: Subjects 40 years of age or older at Visit 1.
  • Gender: Male or female subjects. A female is eligible to enter and participate if of non-, or if of child bearing potential, has a negative serum pregnancy test at screening, and agrees to one of the acceptable methods listed in the protocol, used consistenty and correctly.
  • Diagnosis: An established clinical history of in accordance with the definition by the American Thoracic Society/European Respiratory Society.
  • Smoking History: Current or former cigarette smokers with a history of cigarette smoking of ≥10 pack-years [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Pipe and/or cigar use cannot be used to calculate pack year history.
  • Severity of Disease: A pre and post-albuterol/salbutamol /FVC ratio of \<0.70 and a pre and post-albuterol/salbutamol FEV1 of ≤70% of predicted normal values at Visit 1 (Screening) calculated using Nutrition Health and Examination Survey (NHANES) III reference equations.
  • Dyspnea: A score of ≥2 on the mMRC Dyspnea Scale at Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • Asthma: A current diagnosis of asthma.
  • Other Respiratory Disorders: Known α-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer are absolute exclusionary conditions. A subject who, in the opinion of the investigator, has any other significant respiratory conditions in addition to should be excluded. Examples may include bronchiectasis, pulmonary hypertension, sarcoidosis, or interstitial lung disease.
  • Other Diseases/Abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for \<5 years prior to Visit 1 (localized carcinoma of the skin that has been resected for cure is not exclusionary). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  • : Any history of allergy or to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, sympathomimetic, (intranasal, inhaled or systemic) lactose/milk protein or magnesium stearate, or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholingeric.
  • Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.
  • Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Visit 1.
  • 12-Lead : An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1. Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility.

Specific ECG findings that preclude subject eligibility are listed in Appendix 4. The study investigator will determine the medical significance of any ECG abnormalities not listed in Appendix 4.

  • Medication Prior to Spirometry: Unable to withhold albuterol/salbutamol for the 4 hour period required prior to spirometry testing at each study visit.
  • Medications Prior to Screening: Use of the medications listed in the protocol according to protocol-specific times prio to visit 1.
  • Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., ≤12 hours per day) is not exclusionary.
  • Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (e.g., albuterol/salbutamol) via nebulized therapy.
  • Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded.
  • Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.
  • Affiliation with Investigator Site: A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, subinvestigator, study coordinator, or employee of the participating investigator.
  • Inability to read: In the opinion of the investigator, any subject who is unable to read and/or would not be able to complete a questionnaire.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
617 participants (actual)

Study arms

  • Experimental
    Umeclidinium bromide 62.5 + Fluticasone propionate/Salmeterol

    Long-acting muscarinic antagonist (LAMA), 62.5mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg

    Drug: Umeclidinium bromide 62.5mcg · Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg

  • Active comparator
    Umeclidinium bromide 125 + Fluticasone propionate/Salmeterol

    Long-acting muscarinic antagonist (LAMA), 125mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg

    Drug: Umeclidinium bromide 125mcg · Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg

  • Placebo comparator
    Placebo + Fluticasone propionate/Salmeterol

    Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg

    Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 85 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on Treatment Day 84 (i.e., at Week 12). Baseline trough FEV1 is the mean of the two assessments made at -30 and -5 minutes (min) pre-dose on Treatment Day 1. Change from Baseline was calculated as the Day 85 value minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made at -30 and -5 min pre-dose on Treatment Day 1), smoking status, day, day by Baseline and day by treatment interactions.

    Time frame: Baseline and Day 85

Secondary outcomes

  1. Change From Baseline in Weighted Mean 0-6 Hour FEV1 Obtained Post-dose at Day 84

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean FEV1 was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. The weighted mean was calculated using the 24-hour serial FEV1 measurements at Day 84, which included pre-dose, and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Baseline trough FEV1 is the mean of the two assessments made at -30 and -5 min pre-dose on Treatment Day 1. Change from Baseline was calculated as the Day 84 value minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made at -30and -5 min pre-dose on Treatment Day 1), smoking status, day, day by Baseline and day by treatment interactions.

    Time frame: Baseline and Day 84

  2. Change From Baseline in the Mean Percentage of Rescue-free Days Over Weeks 1-12

    A rescue-free day is defined as a day on which no rescue medication was taken. Baseline calculations include a period of the later of 27 days before Visit 2 and the day after Visit 1, up to and including Day 1. The Weeks 1-12 calculations include a period from Study Day 2 up to the earlier of Study Day 85 and the day before Visit 7. Change from Baseline was calculated as the Weeks 1-12 value minus the Baseline value.

    Time frame: Baseline and Weeks 1-12

  3. Change From Baseline in the Mean Number of Puffs Per Day of Rescue Albuterol/Salbutamol Over Weeks 1-12

    The mean number of puffs per day of rescue albuterol/salbutamol at Baseline and on-treatment was recorded. The total puffs of rescue albuterol/salbutamol for each day was calculated as: (number of puffs + \[2 \* number of nebules\]). Baseline calculations include a period of the later of 27 days before Visit 2 and the day after Visit 1, up to and including Day 1. The Weeks 1-12 calculations include a period from Study Day 2 up to the earlier of Study Day 85 and the day before Visit 7. Change from Baseline was calculated as the Weeks 1-12 value value minus the Baseline value. Analysis was performed using an analysis of covariance (ANCOVA) model with covariates of treatment, Baseline (mean during the 4 weeks prior to Day 1), and smoking status.

    Time frame: Baseline and Weeks 1-12

07

Results

Posted Apr 16, 2014

Participant flow

A total of 682 participants who met the eligibility criteria at Screening (Visit 1) started a 28-day Run-in Period, in which they received open-label fluticasone propionate and salmeterol (FSC) 250/50 micrograms (µg), prior to being randomized to a 12-week randomized Treatment Period.

Participant flow — Overall Study
MilestonePlacebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BID
Started207204206
Received randomized study medication205204205
Completed178190184
Not completed291422
Withdrew: Adverse event6510
Withdrew: Withdrew consent315
Withdrew: Lost to follow-up200
Withdrew: Protocol deviation433
Withdrew: Lack of efficacy1153
Withdrew: Protocol-defined stopping criteria100
Withdrew: Randomized study medication not received201

Outcome measures

PrimaryChange From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 85 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on Treatment Day 84 (i.e., at Week 12). Baseline trough FEV1 is the mean of the two assessments made at -30 and -5 minutes (min) pre-dose on Treatment Day 1. Change from Baseline was calculated as the Day 85 value minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made at -30 and -5 min pre-dose on Treatment Day 1), smoking status, day, day by Baseline and day by treatment interactions.

Time frame:
Baseline and Day 85
Reported as:
Least squares mean · Liters
Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85
LitersPlacebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BID
Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85-0.022 ± 0.01460.125 ± 0.01420.116 ± 0.0144
Statistical analysis
  • Placebo QD + FSC 250/50 µg BID vs UMEC 62.5 µg QD + FSC 250/50 µg BID · Mixed Models Analysis · p = <0.001 · Mean difference (net): 0.147 · 95% CI 0.107 to 0.187
  • Placebo QD + FSC 250/50 µg BID vs UMEC 125 µg QD + FSC 250/50 µg BID · Mixed Models Analysis · p = <0.001 · Mean difference (net): 0.138 · 95% CI 0.097 to 0.178
SecondaryChange From Baseline in Weighted Mean 0-6 Hour FEV1 Obtained Post-dose at Day 84

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean FEV1 was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. The weighted mean was calculated using the 24-hour serial FEV1 measurements at Day 84, which included pre-dose, and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Baseline trough FEV1 is the mean of the two assessments made at -30 and -5 min pre-dose on Treatment Day 1. Change from Baseline was calculated as the Day 84 value minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made at -30and -5 min pre-dose on Treatment Day 1), smoking status, day, day by Baseline and day by treatment interactions.

Time frame:
Baseline and Day 84
Reported as:
Least squares mean · Liters
Change From Baseline in Weighted Mean 0-6 Hour FEV1 Obtained Post-dose at Day 84
LitersPlacebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BID
Change From Baseline in Weighted Mean 0-6 Hour FEV1 Obtained Post-dose at Day 840.032 ± 0.01400.196 ± 0.01380.192 ± 0.0138
SecondaryChange From Baseline in the Mean Percentage of Rescue-free Days Over Weeks 1-12

A rescue-free day is defined as a day on which no rescue medication was taken. Baseline calculations include a period of the later of 27 days before Visit 2 and the day after Visit 1, up to and including Day 1. The Weeks 1-12 calculations include a period from Study Day 2 up to the earlier of Study Day 85 and the day before Visit 7. Change from Baseline was calculated as the Weeks 1-12 value minus the Baseline value.

Time frame:
Baseline and Weeks 1-12
Reported as:
Mean · Percentage of days
Change From Baseline in the Mean Percentage of Rescue-free Days Over Weeks 1-12
Percentage of daysPlacebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BID
Change From Baseline in the Mean Percentage of Rescue-free Days Over Weeks 1-124.9 ± 25.6613.3 ± 28.6611.1 ± 25.70
SecondaryChange From Baseline in the Mean Number of Puffs Per Day of Rescue Albuterol/Salbutamol Over Weeks 1-12

The mean number of puffs per day of rescue albuterol/salbutamol at Baseline and on-treatment was recorded. The total puffs of rescue albuterol/salbutamol for each day was calculated as: (number of puffs + \[2 \* number of nebules\]). Baseline calculations include a period of the later of 27 days before Visit 2 and the day after Visit 1, up to and including Day 1. The Weeks 1-12 calculations include a period from Study Day 2 up to the earlier of Study Day 85 and the day before Visit 7. Change from Baseline was calculated as the Weeks 1-12 value value minus the Baseline value. Analysis was performed using an analysis of covariance (ANCOVA) model with covariates of treatment, Baseline (mean during the 4 weeks prior to Day 1), and smoking status.

Time frame:
Baseline and Weeks 1-12
Reported as:
Least squares mean · puffs
Change From Baseline in the Mean Number of Puffs Per Day of Rescue Albuterol/Salbutamol Over Weeks 1-12
puffsPlacebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BID
Change From Baseline in the Mean Number of Puffs Per Day of Rescue Albuterol/Salbutamol Over Weeks 1-12-0.2 ± 0.09-0.5 ± 0.09-0.5 ± 0.09

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) are defined as those events occurring while participants were on treatment or those events with an onset during the follow-up period (up to 13 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo QD + FSC 250/50 µg BID—8/205 (3.9%)21/205 (10.2%)
UMEC 62.5 µg QD + FSC 250/50 µg BID—4/204 (2%)20/204 (9.8%)
UMEC 125 µg QD + FSC 250/50 µg BID—6/205 (2.9%)22/205 (10.7%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventPlacebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BID
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders3/2052/2041/205
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/2051/2040/205
Vocal cord polypRespiratory, thoracic and mediastinal disorders0/2051/2040/205
Duodenal ulcerGastrointestinal disorders0/2051/2040/205
Upper gastrointestinal haemorrhageGastrointestinal disorders0/2051/2040/205
Chronic sinusitisInfections and infestations0/2051/2040/205
PneumoniaInfections and infestations0/2051/2040/205
Deep vein thrombosisVascular disorders0/2051/2040/205
EpistaxisRespiratory, thoracic and mediastinal disorders0/2050/2041/205
Cardio-respiratory arrestCardiac disorders0/2050/2041/205
Most frequent other events
Most frequent other events
EventPlacebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BID
HeadacheNervous system disorders10/2059/20413/205
NasopharyngitisInfections and infestations10/2055/2045/205
CoughRespiratory, thoracic and mediastinal disorders3/2057/2045/205

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BIDTotal
Mean63.4 ± 8.2762.7 ± 7.8463.2 ± 8.9563.1 ± 8.36
Sex: Female, Male
Sex: Female, Male(Participants)Placebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BIDTotal
Female737163207
Male132133142407
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BIDTotal
African American/African Heritage45312
American Indian or Alaska Native0011
Japanese/East Asian Heritage/ South East Asian20241963
White181175182538
08

Study locations

73 sites
  • GSK Investigational Site
    Jasper, Alabama 35501, United States
  • GSK Investigational Site
    Clearwater, Florida 33765, United States
  • GSK Investigational Site
    Ormond Beach, Florida 32174, United States
  • GSK Investigational Site
    Lafayette, Indiana 47904, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70115, United States
  • GSK Investigational Site
    Edina, Minnesota 55435, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63141, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Easley, South Carolina 29640, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Union, South Carolina 29379, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Morgantown, West Virginia 26505, United States
  • GSK Investigational Site
    Vancouver, British Columbia V6J 1S3, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R2K 3S8, Canada
  • GSK Investigational Site
    Bay Roberts, Newfoundland and Labrador A0A 1G0, Canada
  • GSK Investigational Site
    Truro, Nova Scotia B2N 1L2, Canada
  • GSK Investigational Site
    Burlington, Ontario L7N 3V2, Canada
  • GSK Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • GSK Investigational Site
    Sudbury, Ontario P3E 1H5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1N8, Canada
  • GSK Investigational Site
    Toronto, Ontario M9W 4L6, Canada
  • GSK Investigational Site
    Gatineau, Quebec J8Y 6S8, Canada
  • GSK Investigational Site
    Mirabel, Quebec J7J 2K8, Canada
  • GSK Investigational Site
    Montreal, Quebec H2R 1V6, Canada
  • GSK Investigational Site
    St-Charles-Borromée, Quebec J6E 2B4, Canada
  • GSK Investigational Site
    St-Romuald, Quebec G6W 5M6, Canada
  • GSK Investigational Site
    Trois Rivières, Quebec G8T 7A1, Canada
  • GSK Investigational Site
    Quebec, G1V 4G5, Canada
  • GSK Investigational Site
    Quebec, G3K 2P8, Canada
  • GSK Investigational Site
    Sinsheim, Baden-Wuerttemberg 74889, Germany
  • GSK Investigational Site
    Stuttgart, Baden-Wuerttemberg 70378, Germany
  • GSK Investigational Site
    Bamberg, Bayern 96049, Germany
  • GSK Investigational Site
    Schwabach, Bayern 91126, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60389, Germany
  • GSK Investigational Site
    Gelnhausen, Hessen 63571, Germany
  • GSK Investigational Site
    Kassel, Hessen 34121, Germany
  • GSK Investigational Site
    Schwerin, Mecklenburg-Vorpommern 19055, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30159, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30173, Germany
  • GSK Investigational Site
    Weyhe-Leeste, Niedersachsen 28844, Germany
  • GSK Investigational Site
    Dueren, Nordrhein-Westfalen 52349, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45355, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45359, Germany
  • GSK Investigational Site
    Goch, Nordrhein-Westfalen 47574, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 51069, Germany
  • GSK Investigational Site
    Witten, Nordrhein-Westfalen 58452, Germany
  • GSK Investigational Site
    Koblenz, Rheinland-Pfalz 56068, Germany
  • GSK Investigational Site
    Magdeburg, Sachsen-Anhalt 39112, Germany
  • GSK Investigational Site
    Teuchern, Sachsen-Anhalt 6682, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01069, Germany
  • GSK Investigational Site
    Leipzg, Sachsen 04109, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04103, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04207, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04357, Germany
  • GSK Investigational Site
    Luebeck, Schleswig-Holstein 23552, Germany
  • GSK Investigational Site
    Reinfeld, Schleswig-Holstein 23858, Germany
  • GSK Investigational Site
    Gera, Thueringen 07548, Germany
  • GSK Investigational Site
    Schmoelln, Thueringen 04626, Germany
  • GSK Investigational Site
    Berlin, 13125, Germany
  • GSK Investigational Site
    Berlin, 13156, Germany
  • GSK Investigational Site
    Berlin, 14059, Germany
  • GSK Investigational Site
    Hamburg, 22143, Germany
  • GSK Investigational Site
    Hamburg, 22299, Germany
  • GSK Investigational Site
    Hamburg, 22767, Germany
  • GSK Investigational Site
    Bucheon-si,, 420-767, Korea, Republic of
  • GSK Investigational Site
    Cheongju, Chungcheongbuk-do, 361-711, Korea, Republic of
  • GSK Investigational Site
    Kangwon-do, 220-701, Korea, Republic of
  • GSK Investigational Site
    Seoul, 130-872, Korea, Republic of
  • GSK Investigational Site
    Seoul, 136-705, Korea, Republic of
  • GSK Investigational Site
    Seoul, 137-701, Korea, Republic of
  • GSK Investigational Site
    Seoul, 156-707, Korea, Republic of
  • GSK Investigational Site
    Suwon, Gyeonggi-do, 442-723, Korea, Republic of
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2013
First posted
Jan 21, 2013
Start
Jan 1, 2013
Primary completionActual
Jul 1, 2013
CompletionActual
Jul 22, 2013
Results first posted
Apr 16, 2014
Last update
Jan 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01772134
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 21, 2013
Start date
Jan 1, 2013
Primary completion
Jul 1, 2013
Completion
Jul 22, 2013
Results posted
Apr 16, 2014
Last update
Jan 29, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Umeclidinium bromide

Start the discussion